Even before the recent Russian incursion into Ukraine, global supply chains were stressed by various factors. Many companies and processors are still recovering from challenges—labor shortages and limited resources to name a few—caused by the 2020 pandemic. Now, we have geopolitical tension in Asia. The active fighting between Russian and Ukrainian forces is doing more than causing global distress. It’s also directly affecting the pharmaceutical industry, where complex supply chains are often globally connected. Why are pharma companies paying attention to notices like the cessation of port visits in the region by shippers like A.P. Moller-Maersk?
To ensure that their supply chain continues to function as smoothly as possible by accounting for issues caused by international events.
Pharma Companies and Raw Materials
Russians have traditionally exported raw materials to the U.S., often classifying minerals as a key export. This includes a range of items commonly classified as inorganic chemicals.
Similarly, several other countries have their own exports that the markets rely on for stability. With many export and import processes applying to drug manufacturing and pharmaceutical sales, companies are looking for alternate arrangements. They’re opting out of delivery in certain parts of the region based on current hostilities, forcing firms to seek another way to process and receive their transatlantic deliveries and avoid supply chains disruptions.